AMRI’s Buffalo, NY site has been selected to participate as a Dedicated Chemical Biology Consortium  (CBC) Center for the Experimental Therapeutics (NExT) Program, centered at the Frederick National Lab for Cancer Research.

The Frederick National Lab, sponsored by the National Cancer Institute, is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. AMRI is participating in the consortium via a research subcontract from Leidos Biomedical Research, Inc., prime contractor for the national lab.

The Chemical Biology Consortium is the discovery arm for the NCI Experimental Therapeutics (NExT) Program focused on advancing new cancer therapies. AMRI’s Buffalo facility will provide a variety of drug discovery services to the consortium for a period of five years.

“Being selected as a dedicated center for the NExT program is a reflection of AMRI’s commitment and strength as a partner for oncology drug development,” said Christopher Conway, senior vice president of Discovery and Development Services at AMRI. “Our integrated drug discovery facility in Buffalo combines multiple scientific disciplines, state of the art technologies, and the capabilities to advance from compound discovery through pharmaceutical product manufacturing – all under one roof. This accelerates drug development by promoting cross-disciplinary collaboration, enabling faster transfer of data and providing partners with greater access via single points of contact. This is especially valuable in oncology drug development, where there is a tremendous emphasis for drug researchers to pursue new and more complex avenues of cancer drug development.”